<code id='6FA3BAF22D'></code><style id='6FA3BAF22D'></style>
    • <acronym id='6FA3BAF22D'></acronym>
      <center id='6FA3BAF22D'><center id='6FA3BAF22D'><tfoot id='6FA3BAF22D'></tfoot></center><abbr id='6FA3BAF22D'><dir id='6FA3BAF22D'><tfoot id='6FA3BAF22D'></tfoot><noframes id='6FA3BAF22D'>

    • <optgroup id='6FA3BAF22D'><strike id='6FA3BAF22D'><sup id='6FA3BAF22D'></sup></strike><code id='6FA3BAF22D'></code></optgroup>
        1. <b id='6FA3BAF22D'><label id='6FA3BAF22D'><select id='6FA3BAF22D'><dt id='6FA3BAF22D'><span id='6FA3BAF22D'></span></dt></select></label></b><u id='6FA3BAF22D'></u>
          <i id='6FA3BAF22D'><strike id='6FA3BAF22D'><tt id='6FA3BAF22D'><pre id='6FA3BAF22D'></pre></tt></strike></i>

          fashion

          fashion

          author:fashion    Page View:4
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          Heart attack and stroke risk calculators need revising
          Heart attack and stroke risk calculators need revising

          AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

          read more
          A single drug, study failures leave Anavex with nothing but cash
          A single drug, study failures leave Anavex with nothing but cash

          MollyFerguson/STATIttookAnavexLifeSciencessevenmonthstofinallyacknowledgethefailureofalate-stageclin

          read more
          Hepatitis C has a cure — but many Americans still lack access to it
          Hepatitis C has a cure — but many Americans still lack access to it

          AdobeIn2005,NickVoyleswasdiagnosedwithhepatitisCafterbeingreleasedfromfiveyearsofincarceration.Anurs

          read more

          Morgan Health, with ambitious aims, wants you to know it’s still here

          AdobeSANFRANCISCO—Almostthreeyearsago,thecountry’sbiggestbankunveiledaloftyplantofixthehealthcareind